Temporarily Implanted Prostatic Stents for Benign Prostatic Hyperplasia

This policy covers temporary implanted prostatic stents (temporary/removable nitinol devices such as iTind and Spanner®) for relief of prostatic urethral obstruction from symptomatic benign prostatic hyperplasia (BPH) — including LUTS, urinary retention, post-radiation obstruction, recurrent UTIs/bladder stones, or as a short-term alternative to an indwelling catheter or TURP in patients who have not tolerated or responded to medical therapy. Major limitations/requirements: these devices are considered experimental/investigational/unproven for LUTS due to BPH, are intended for short-term use (typically removed after 5–7 days; Spanner® up to 30 days), medical therapy is preferred first-line, and certain device-specific indications/age limits apply (e.g., iTind for men ≥50).

"Symptomatic benign prostatic hyperplasia (BPH) causing prostatic urethral obstruction"

Sign up to see full coverage criteria, indications, and limitations.